US Stock MarketDetailed Quotes

RARE Ultragenyx Pharmaceutical

Watchlist
  • 42.920
  • +0.950+2.26%
Close Feb 28 16:00 ET
  • 42.920
  • 0.0000.00%
Post 16:55 ET
3.97BMarket Cap-6.82P/E (TTM)

Ultragenyx Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Ultragenyx Pharmaceutical Q4 2024 Earnings Date

Currency：USDFeb 13, 2025

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
158.71M
164.88M
+6.17M
Beat Est.
+24.58%
+29.42%
+3.89%
EPS
-1.29
-1.39
-0.10
Miss Est.
+15.12%
+8.55%
-7.74%
Analyst Rating
Strong Buy

Mar 1, 2025

Ultragenyx Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 16 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 163.669M--
--2025/Q1-- / 145.980M--
Feb 13, 20252024/Q4164.877M / 158.706M--
Nov 5, 20242024/Q3139.494M / 135.247M--
Aug 1, 20242024/Q2147.026M / 123.214M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 163.669M--
--2025/Q1-- / 145.980M--
Feb 13, 20252024/Q4164.877M / 158.706M--
Nov 5, 20242024/Q3139.494M / 135.247M--
Aug 1, 20242024/Q2147.026M / 123.214M--

Unlock Free Earnings Estimates

Ultragenyx Pharmaceutical Earnings Reports

  • Ultragenyx Pharmaceutical | 10-K: FY2024 Annual Report

    Feb 19 17:02 ET

  • Ultragenyx Pharmaceutical | 8-K: Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

    Feb 13 16:11 ET

  • Ultragenyx Pharmaceutical | 10-Q: Q3 2024 Earnings Report

    Nov 6, 2024 13:11 ET

  • Ultragenyx Pharmaceutical | 8-K: Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

    Nov 5, 2024 16:13 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Cars.com
    CARS
    +9.73%
    Lantheus
    LNTH
    +2.55%
    Halozyme Therapeutics
    HALO
    +2.51%
    DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
    DMZPY
    +2.27%
    Collegium Pharmaceutical
    COLL
    +2.22%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Mar 1, 2025

    Strong Buy

    • Buy

      93.75%

    • Hold

      6.25%

    • Sell

      0.00%

    Price Target

    No Data